STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #431 by analyst upside · 2026-06-27
AARD
Aardvark Therapeutics, Inc.
Healthcare · Market Cap $105M · P/E 0x
ANALYST PRICE TARGET
+222.4%
implied upside to consensus target
Current Price $4.79
Consensus Target $15.44
Bull Target $45.0
Bear Target $3.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
6
Hold
3
Sell
0
52-Week Low $3.35
52-Week High $17.94
YTD Return -63.7%
FUNDAMENTALS
Market Cap $105M
P/E Ratio (TTM) N/A
Forward P/E -1.5x
EPS (TTM) $-3.04
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.35
52-Week High $17.94
Current Price $4.79
Bear Target $3.0
Bull Target $45.0
● Now $4.79 ● Target $15.44
TRADING DATA
Avg Volume 195K
YTD Return -63.7%
Analyst Count 9
Consensus Buy
Upside to Target +222.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Aardvark Therapeutics, Inc. (AARD) is currently trading at $4.79 with a Wall Street consensus price target of $15.44, implying potential upside of 222.4% over the next 12 months. 9 analysts currently cover AARD, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $3.0.

AARD operates in the Healthcare sector with a market capitalisation of $105M. The stock is down 63.7% year-to-date and is currently trading near the lower end of its 52-week range of $3.35 – $17.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AARD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B. Riley Securities — Reiterated
Buy → Buy 2026-05-15 17% win rate (6 calls)
BTIG ↓ Downgrade
Buy → Neutral 2026-05-15 38% win rate (8 calls)
Morgan Stanley ↓ Downgrade
Equal-Weight → Underweight 2026-05-15 Building track record
BTIG reit
Buy → Buy 2026-03-24 38% win rate (8 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-02 14% win rate (7 calls)
BTIG — Reiterated
Buy → Buy 2026-03-02 38% win rate (8 calls)
Morgan Stanley ↓ Downgrade
Overweight → Equal-Weight 2026-03-02 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-03-02 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
32
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →